Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.
Official title: An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "DWJ1622" and Co-administration of "DWC202313" and "DWC202314" in Healthy Volunteers
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2025-12-01
Completion Date
2026-05-30
Last Updated
2025-12-05
Healthy Volunteers
Yes
Conditions
Interventions
DWJ1622
DWJ1622 (single oral dose) is administered in accordance with the study protocol.
DWC202313, DWC202314
DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.
Locations (1)
H Plus YANGJI Hospital
Seoul, Gwanak-gu, South Korea